Lorraine Portelance MD FASTRO

Radiation Oncology•Tampa, FL

Gastrointestinal Cancer, Gynecologic Cancer

Vice Chair/Clinic Division Chief

Join to View Full Profile

12902 USF Magnolia DrTampa, FL 33612
Phone+1 786-266-2811

Summary

Lorraine Portelance, MD, is a Radiation Oncologist located in Tampa, FL, serving as the Vice Chair/Clinical Division Chief at Moffitt Comprehensive Cancer Center. She graduated from the University of Montreal Faculty of Medicine in 1997. Dr. Portelance has expertise in on-board adaptive therapy, brachytherapy, endometrial cervical and lower GI neoplasms. Her academic contributions include multiple publications focused on advanced radiation therapy techniques and cancer treatment guidelines. She has been the Principal Investigator in several clinical trials, and her work has been recognized with honors, such as being named a Regional Top Doctor by Castle Connolly in 2014 and American Society of Radiation Oncology Fellow in 2017.

Education & Training

University of Montreal Faculty of MedicineClass of 1997

Certifications & Licensure

FL State Medical License 2010 - 2026
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Start of enrollment: 2010 Apr 05
ACTIVE_NOT_RECRUITING
PHASE3
MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer Start of enrollment: 2011 Dec 27
Completed
Not Applicable
Hypofractionated Image-Guided Radiotherapy For Prostate Cancer: The HEIGHT Trial Start of enrollment: 2011 Oct 31
Completed
Not Applicable
MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial Start of enrollment: 2012 Jul 12
Active, not recruiting
Not Applicable
Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer Start of enrollment: 2012 Jan 01
Completed
Phase 1
Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer Start of enrollment: 2011 Oct 13
COMPLETED
PHASE2, PHASE3
Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Start of enrollment: 2012 Nov 01
Completed
Phase 3
LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma Start of enrollment: 2014 May 01
Withdrawn
Phase 1
Follow-up Yttrium-90 Internal Pair Production PET/CT vs Brehmsstrahlung Imaging in Patients With Primary/Metastatic Liver Tumors Start of enrollment: 2013 Apr 01
Completed
Not Applicable
SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer Start of enrollment: 2022 Oct 05
RECRUITING
PHASE1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Analgesia and Anesthesia Practice Patterns for Gynecologic Brachytherapy Procedures and Potential Impact on Women's Procedural Experience: A National Survey.
Amanda Rivera, Dulce M Barrios, Emma Herbach, Jenna M Kahn, Vonetta M Williams
International Journal of Radiation Oncology, Biology, Physics. 2025-01-01
Potential to reduce margins and Shrink targets in patients with intact cervical cancer treated on An MRI guided radiation therapy (MRgRT) system.
Lorraine Portelance, David Asher, Ricardo Llorente, Eric Mellon, Aaron Wolfson
Physica Medica. 2025-01-01
Consensus Guidelines for Delineation of Clinical Target Volumes for Intensity Modulated Radiation Therapy for Intact Cervical Cancer: An Update.
Emma C Fields, Walter R Bosch, Kevin V Albuquerque, Rohini Bhatia, Junzo Chino
Practical Radiation Oncology. 2024-11-13

Press Mentions

ASTRO to Feature ViewRay's MRIdianSeptember 10th, 2019
Technology Aiding the Fight Against Cancer’s TumorsMay 25th, 2016